CytoSorbents Corporation (CTSO)

[techxen]

I saw this as well and downloaded the published study from SCRIBD

https://www.scribd.com/document/448385523/s-2213260020300795#download

This is very significant in that it is the first published study of the mortality of patients with SARS-CoV-2 pneumonia in Wuhan, China. Now the world gets to see the REAL numbers.

Since the Wuhan coronavirus first appeared late last year, researchers have been studying it, though for the first month or so, only Chinese scientists had access to the data. But now that China has shared its data with the world, research has been appearing more quickly, with more opportunities for peer review. According to a study published in the Lancet on Friday, patients who are especially vulnerable to severe COVID-19 infections - a group that includes the very old, very young and those with co-occurring conditions - die at a higher rate from COVID-19 than they did from SARS and MERS.

A study of 52 critically ill adults at Wuhan Jin Yin-tan hospital found that 61.5% of patients requiring hospitalization and intense monitoring ended up becoming "non-survivors", to borrow some of the researchers' terminology. The researchers concluded that COVID-19 - or SARS-CoV-2, as they call it - is more lethal for vulnerable patients than SARS or MERS was.

The study was based on 710 patients who were diagnosed with COVID-19 and out of these 201 ended up with pneumonia and out of these 52 were admitted to the ICU in critical condition (these are the patients that Cytosorb is targeting) - so almost 8% of those getting the virus end up in the ICU. Of these 32 (61·5%) patients had died at 28 days, and the median duration from ICU admission to death was 7 days !!!

This is much higher than people originally thought. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax (table 2). Hospital-acquired infection was noted in seven (13·5%) patients, including one (2%) patient who had pulmonary and blood stream infection of carbapenem-resistant Klebsiella pneumoniae. Cytosorbents has published case studies for patients having all of these conditions and were successfully treated.